glp 1 3rd generation Triple Agonism Based Therapies for Obesity cravings and metabolic efficiency for effortless weight loss without medications. Lindsay Maggio, MD, MPH |

T2D patients with severe renal impairment are not eligible for SGLT2 inhibitors, and GLP-1RAs could be an important therapeutic option for these patients

Photosensitivity is not listed among known adverse effects in UK product information or MHRA guidance

Diabetologia (2011) 54(8):206776

It regulates blood sugar by boosting insulin secretion, reducing glucagon release, and slowing digestion to promote satiety

A common implementation: eating window from 11am to 7pm, or 12pm to 8pm

Semaglutide GLP-1 affects the hypothalamus region of the brain, slowing down how fast the stomach empties and delaying gastric emptying into the intestine